Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 2005 Jan 1;23(1):165-74. Epub 2004 Nov 22.

Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Author information

  • 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.



The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer.


This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response.


We present our recommendations for the management of rash and diarrhea caused by this agent.


This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk